Clinical trials: Vascular And Immunologic Diseases
Multiple Myeloma, Amyloidosis
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Captisol Enabled Melphalan, is a new formulation of the standard of care melphalan chemotherapy that in packaged in an inactive substance that is believed to help the chemotherapy be more stable (meaning that it doesn't lose its…
- Trial name
- NCT02909036
- Testing
- Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Coronavirus Disease 2019
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections.
- Trial name
- NCT04401436
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leukemia, Acute, Myelodysplastic Syndromes
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell…
- Conditions
- Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia
- Trial name
- NCT05823571
- Testing
- Itacitinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chronic Obstructive Pulmonary Disease, Asthma
Hyperoxia During Pulmonary Rehabilitation in Chronic Lung Disease - Does it Matter?
Chronic respiratory diseases are a global burden. Treatment options have improved in recent years, pulmonary rehabilitation plays a key role.
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Pulmonary Hypertension, Interstitial Lung Disease
- Trial name
- NCT06174207
- Testing
- Oxygen
- Where
- Switzerland
- Volunteers
- 23 people
- Sponsor
- Eastern Switzerland University of Applied Sciences
Multiple Myeloma
ASCT With Nivolumab in Patients With Multiple Myeloma
This is an open-label, single center trial of Autologous Stem Cell Transplantation (ASCT) with nivolumab in multiple myeloma patients to determine the efficacy and safety of ASCT and PD1 inhibitor combination.
- Trial name
- NCT03292263
- Testing
- Melphalan, Nivolumab, Autologous Stem Cell Transplantation
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- St. Petersburg State Pavlov Medical University
HIV/AIDS, Hypertension
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
Strategies to improve uptake of cardiovascular disease preventive therapies among people living with HIV (PLHIV) are urgently needed.
- Conditions
- HIV/AIDS, Hypertension, Hyperlipidemias
- Trial name
- EXTRA-CVD (NCT03643705)
- Testing
- Multi-component intervention, General prevention education
- Where
- 3 sites in United States
- Volunteers
- 298 people
- Sponsor
- Case Western Reserve University
Anemia, Thrombocytopenia
Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence
Determine whether clinical decision support (best practice advisory) improves provider adherence to transfusion guidelines for all four major blood components (red blood cells, plasma, platelets, and cryoprecipitate) using a…
- Conditions
- Anemia, Thrombocytopenia, Coagulopathy, Mild, Hypofibrinogenemia
- Trial name
- NCT05634005
- Testing
- Clinical Decision Support
- Where
- United States
- Volunteers
- 1,543 people
- Sponsor
- University of Utah
Multiple Myeloma
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
This study will use the drug daratumumab in patients who did not achieve at least a very good partial response (VGPR) and are already planned to have an Autologous Stem Cell Transplant (ASCT).
- Trial name
- NCT04230031
- Testing
- Daratumumab
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Pain, Pain Syndrome
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06072001
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Multiple Myeloma
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
To evaluate the efficacy and safety of investigational drug Colchicine combined with conventional lenalidomide based therapy in multiple myeloma subjects who had received first-line therapy (including Chimeric antigen receptor…
- Trial name
- NCT05802992
- Testing
- Colchicine, Lenalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Atopic Dermatitis, Psoriasis
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable.
- Conditions
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus
- Trial name
- ImmuneSkinBank (NCT06599411)
- Testing
- Sampling
- Where
- France
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
The purpose of this study is to find out whether combination treatment with the study drugs belantamab mafodotin, nirogacestat, and pomalidomide is a safe treatment for people who have relapsed or refractory multiple myeloma.
- Trial name
- NCT05556798
- Testing
- Belantamab Mafodotin, Nirogacestat, Pomalidomide
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Normal Pregnancy
Determination of Reference Values for Diluted Russell's Viper Venom Time (dRVVT) Specific to Pregnant Women (GRAPL)
Pregnancy is associated with significant changes in several aspects of haemostasis, especially an imbalance between procoagulant and anticoagulant factors.
- Trial name
- GRAPL (NCT06133621)
- Testing
- dosage dRVVT
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Hereditary Angioedema (HAE)
A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People
This study intends to gather information on HAE attack symptoms, how often the attacks occur, and the number of times treatment is required to manage the attacks in Korean people over a period of up to 11 months.
- Trial name
- SPEAKUP (NCT06587464)
- Testing
- No Intervention
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Takeda
Multiple Myeloma
Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients
1. Description of the demographic, clinical, and laboratory characteristics of patients with MM admitted to the hematology unit of Assuit University Hospitals. 2.
- Trial name
- NCT06457464
- Testing
- Chemotherapy
- Volunteers
- 100 people
- Sponsor
- Assiut University
Multiple Myeloma
A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
This clinical trial evaluates the impact of a plant-based whole-foods delivery service on the microbiome in patients with multiple myeloma undergoing an autologous hematopoietic cell transplant.
- Trial name
- NCT06559709
- Testing
- Biospecimen Collection, Dietary Intervention, Medical Chart Review
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma (MM)
Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"
This is a multicenter, observational, retrospective-prospective study designed to validate the predictive role of advanced imaging in patients with newly diagnosed multiple myeloma (NDMM).
- Trial name
- NCT07746232
- Testing
- DW-MRI (MY-RADS/RAC score), Fat Fraction (rFF%), Clinical Data Collection
- Where
- 10 sites in Italy
- Volunteers
- 92 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma, New Diagnosis Tumor
A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma
Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma
- Trial name
- NCT05712083
- Testing
- BCMA CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Familial Cold Urticaria
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria.
- Trial name
- NCT00214851
- Testing
- Kineret (anakinra)
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Nova Scotia Health Authority
Multiple Myeloma and Plasma Cell Neoplasm
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00618345
- Testing
- everolimus, DNA analysis, protein analysis
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.